Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative Encorafenib and Binimetinib in BRAFV600 Mutant Melanoma
NCT05097378Phase 2Active, not recruiting
- Sponsor
- Cambridge Clinical Trials Unit
- Start
- Feb 2023
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of encorafenib, binimetinib in melanoma, sponsored by Cambridge Clinical Trials Unit. Started Feb 2023; status: active, not recruiting.
02
Drugs
encorafenibbinimetinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05097378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05097378.